← Eichor
Study identifier: NCT01277419 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

German Spondyloarthritis Inception Cohort

Condition: Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) · Non-radiographic Axial Spondyloarthritis (Nr-axSpA) · Axial Psoriatic Arthritis (axPsA)  ·  Sponsor: Charite University, Berlin, Germany

PhaseN/A
Planned participants1000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

This description comes directly from the study's public registry record.

Talk to the study team

Denis Poddubnyy, Prof. Dr.  ·  +4930450514582  ·  denis.poddubnyy@charite.de

Always discuss trial participation with your own doctor first.

Locations (1)

Charité - Universitätsmedizin BerlinBerlin, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01277419